Lung Cancer

In patients with extensive-stage small cell lung cancer Imdelltra plus chemoimmunotherapy was associated with positive outcomes.

Among patients with EGFR-mutated non-small cell lung cancer Tagrisso plus chemotherapy was associated with an improvement in survival.

Ponsegromab improved body weight, suppressed GDF-15 and was well-tolerated over 64 weeks in cancer-associated cachexia, including patients switching from placebo.

Sevabertinib showed high response rates and durable disease control in patients with HER2-mutant NSCLC, with diarrhea as the main manageable side effect.

LiveLung, a nonprofit organization, invites the CSRA’s lung cancer community to its educational meeting.

Brittney Nichols discussed the emotional and physical side effects of lung cancer treatment, as well as feelings of isolation in newly diagnosed patients.

Brittney Nichols highlights the need for early detection and stresses that lung cancer is not only caused by smoking; anyone can develop the disease.

The FDA granted fast track designation to VT3989 for unresectable malignant nonpleural or pleural mesotherlioma.

LiveLung, a nonprofit organization dedicated to supporting lung cancer patients, invites the Charlotte cancer community to its monthly educational meeting.

As we approach Lung Cancer Awareness Month this November, it’s important to reflect on the latest developments and insights in lung cancer research.

The FDA has approved Zepzelca with Tecentriq or Tecentriq Hybreza for extensive-stage small cell lung cancer.

Lung cancer can be overwhelming, but learning about types, stages, treatments and support can help patients feel more prepared for their care journey.

Prior to my diagnosis with Stage 3B Lung Cancer, I had spent many years reading self-help books. I worked hard, but never felt successful, or took pride in myself.

In September 2025, the FDA approved new treatments for breast, bladder and prostate cancers, plus biosimilars and a subcutaneous immunotherapy option.

Adding Tecentriq to chemoradiation improved quality of life and supported twice-daily radiation for patients with limited-stage small cell lung cancer.

For patients with cancer grappling with nausea or vomiting due to their treatments, a potential side effect remedy may be found in their own hands.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.

Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.

After years of chronic cough and misdiagnosed infections, a 2016 stage 4 ALK-positive lung cancer diagnosis led to targeted therapy that has helped since.

LiveLung announced the launch of its new Chaplain Program.

It is very important to let the world know that no matter how healthy you think you are, if you have lungs, you can potentially develop lung cancer.

The FDA has granted approval to subcutaneous Keytruda for use in adults and pediatric patients with a solid tumor.

Nancee Pronsati discusses a new patient-authored guide for managing ALK-directed treatment side effects in lung cancer and improving quality of life.